Alnylam Pharmaceuticals Reports HELIOS-B Phase 3 Findings: Vutrisiran Reduces Gastrointestinal Events in ATTR-CM Patients Alnylam Pharmaceuticals, Inc. , a global leader in RNA interference (RNAi) therapeutics, today unveiled new analyses from the HELIOS-B Phase 3 study evaluating AMVUTTRA® (vutrisiran). Vutrisiran…
International Day of Older Persons: AOP Health Brings Urgent Attention to the Silent Burden of Venous Leg Ulcers Every year on October 1, the world observes the United Nations’ International Day of Older Persons, a moment dedicated to honoring the…
Quince Therapeutics Publishes Advanced Population PK Modeling Study of eDSP in Pediatric Ataxia-Telangiectasia Patients in CPT: Pharmacometrics & Systems Pharmacology Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company pioneering patient-specific therapies for rare diseases, has announced the publication of…
TAE Life Sciences and University of Wisconsin–Madison Collaborate to Bring Revolutionary Accelerator-Based BNCT Cancer Therapy to the U.S. TAE Life Sciences (TLS), a global innovator in the field of advanced cancer therapies, has joined forces with the University of Wisconsin–Madison…
Potential First Approved Treatment in the EU Targeting NF1-Associated Plexiform Neurofibromas koselugo (selumetinib), an oral, selective MEK inhibitor, has been recommended for approval in the European Union (EU) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adult patients with…
CHMP Recommends EU Approval of Tezspire for Chronic Rhinosinusitis with Nasal Polyps AstraZeneca and Amgen’s Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The Committee…
Merck Secures Dual Positive CHMP Opinions for KEYTRUDA® in Europe: Subcutaneous Administration and New Head & Neck Cancer Indication Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced a major regulatory milestone in Europe as…
Biogen Receives European Commission Approval for ZURZUVAE® (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has granted marketing authorization for ZURZUVAE® (zuranolone) to treat post-partum…
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT) Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced that the European Commission (EC) has approved ROMVIMZA™…
Novo, Lilly Jostle For Market Lead in Obesity With New Regulatory Efforts Both Novo Nordisk and Eli Lilly are eyeing regulatory advancements for their obesity blockbusters as the European Association for the Study of Diabetes’ annual conference continues this week.…
EU approves first oral GLP-1 RA to cut cardiovascular risk Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the Rybelsus® (oral semaglutide) label to reflect the cardiovascular…
AGC Biologics Seattle Facility Celebrates Milestone Year with Regulatory Approvals, Quality Achievements, and Leadership Expansion AGC Biologics, a leading global contract development and manufacturing organization (CDMO), has announced that its Seattle, Washington facility has achieved a series of remarkable milestones…
